














































A sex-specific prediction model is not enough
to achieve equality for women in preventative
cardiovascular medicine
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This commentary refers to ‘SCORE2 risk prediction algo-
rithms: new models to estimate 10-year risk of cardiovascu-
lar disease in Europe’, by the SCORE2 working group and
European Society of Cardiology (ESC) Cardiovascular
Risk Collaboration, https://doi.org/10.1093/eurheartj/
ehab309 and the discussion piece ‘SCORE2 models allow
consideration of sex-specific cardiovascular disease risks by
region’, by S. Hageman et al., https://doi.org/10.1093/
eurheartj/ehab761.
We wish to congratulate Hageman et al.1 for their important study
‘SCORE2 risk prediction algorithms: new models to estimate 10-year
risk of cardiovascular disease in Europe’. The advanced methodo-
logical approach undertaken, and the development of sex-specific
prediction models will improve the prediction of cardiovascular dis-
ease in women and men across Europe.
Awareness of sex inequalities in the provision of cardiovascu-
lar health care is increasing.2,3 Although we highly appreciate the
authors efforts to address this by developing a sex-specific car-
diovascular risk tool, this will not be enough to achieve equality
for women in the area of preventative cardiovascular medicine.
When a sex-specific approach is proposed, it is crucial that the
data is provided on a sex-disaggregated level to aid in the inter-
pretation of performance and to enable further validation of re-
search findings.3,4 It should be mandatory that sufficient details of
the risk algorithms are provided to replicate the findings in both
men and women. This does not only include the end product,
the SCORE2 risk charts, but also the risk equation on which the
risk charts are based upon. Unfortunately, the authors only pre-
sent a male example in their study (Supplemental Methods,
Table 1), therefore precluding further evaluation of the reprodu-
cibility of the SCORE2 risk equation in women.
The components of the SCORE2 risk equation are (i) the sex-
specific beta-coefficients of predictors, (ii) the mean value of which
each predictor is centred, and (iii) the sex-specific 10-year survival for
individuals in the baseline group. For men, all components of the
SCORE2 risk equation are included in the report. For women, the
female-specific beta-coefficients of predictors are not provided, and
the reported female-specific hazard ratios lack precision (rounded by
two decimals) for women on a similar level as for men (rounded by
four decimals). Furthermore, the 10-year survival for women in the
baseline group is not reported, which prevents calculation of risk in
women using the SCORE2 risk equation in other cohorts.
We therefore ask the authors to provide female-specific beta-coeffi-
cients and 10-year baseline survival for women, so that the SCORE2
risk equation can be determined in women in future research to ensure
the findings of this important study can be generalized to both women
and men. This will enable future studies addressing the impact of imple-
menting the SCORE2 risk equation on the prevention of cardiovascular
disease in men and women and will contribute to our shared goal of
sex-equality in the provision of cardiovascular health care.
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